Ulcerative Colitis Treatment & Management
New treatment could help those with Crohn's, colitis
If you are required to provide additional personally identifiable information to access a particular component of the Services, or if we would like to use personally identifiable information that you have previously provided in a manner not otherwise permitted under this Privacy Policy, we will explain how we intend to use such personally identifiable information at the time of collection and will require your consent at that time to any such collection and use. Continuing Medical Education When you participate in a Continuing Medical Education (CME) or a Continuing Education (CE) activity through the Services, you may be asked to provide personally identifiable information such as your name and mailing address. In addition to personally identifiable information, aggregated non-personally identifiable information about the activities undertaken by CME/CE participants is recorded. Information that you provide in connection with your participation in CME/CE activities, either when registering or requesting credit, may be used in several ways: Medscape is accredited by the Accreditation Council for Continuing Medical Education (ACCME) the American Nurses Credentialing Center, and the Accreditation Council for Pharmacy Education to provide continuing education to physicians, nurses and pharmacists, respectively. As an accredited entity, Medscape is required to periodically submit aggregated data about CME/CE participants and the CME/ CE activities that Medscape certifies. Medscape also provides personally identifiable information to other accredited CME/CE providers who certify CME/CE activities offered through the Services, as necessary for their fulfillment of their reporting obligations to the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years; and Supporters of CME/CE activities will receive only aggregated data about CME/CE activities that they support. The Medscape editorial staff has access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Medscape may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and evaluating its education activities. Information from Outside Sources We may collect additional information about registered users from third party sources to assist us in providing the Services. For example, we use such information to verify and update registration information and confirm licensure status. Other Information Discussion Boards: When you post a message to a discussion board, your basic profile will be available for all registered users to see. This basic profile consists of your name, specialty and geographic information. You may, at your option, choose to display additional information in your profile. You should not post any information about you or any other person (including any patient) to a discussion board or other public forum if you want to keep such information private or you are required by law to keep such information private. have a peek at this web-site http://emedicine.medscape.com/article/183084-treatment
Vedolizumab, an intravenous antibody medication, offers new hope for the approximately four million people who suffer from the auto-immune diseases, say researchers who led two clinical trials, the results of which were published in the New England Journal of Medicine on Wednesday. The treatment resulted in remission and allowed patients to stop taking prednisone, a drug with ample side effects used to treat both diseases. "The two trials showed highly encouraging results for patients suffering from moderate to severe Crohn's disease and ulcerative colitis when conventional therapy such as steroids, immune suppressive drugs" and other drugs failed, said William Sandborn of the UC San Diego School of Medicine, who led the Crohn's study. "These latest findings will potentially lead to a new drug therapy that will improve a patient's overall lifestyle," Sandborn said. Vedolizumab, created by Japan's Takeda laboratory, blocks immune system cells that release proteins called cytokines that trigger inflammation, causing diarrhea and tissue damage in the small intestine and colon. The medication could help patients avoid the weight gain, nausea and headaches associated with other treatments for the diseases. Patients could also forgo the steroids and immunosuppressive medication that put them at risk for infection. Crohn's disease and ulcerative colitis cause abdominal pain, diarrhea, intestinal bleeding and weight loss. In severe cases, bowel obstruction, colon cancer, malnutrition and abscesses that necessitate removal of part of the bowel and colon can occur. Clinical trials in 34 countries followed 895 patients with ulcerative colitis and 1,115 patients with Crohn's disease, between the age of 18 and 80. Patients were treated for a year and saw effects after six weeks. address http://www.foxnews.com/health/2013/08/22/new-treatment-could-help-those-with-crohns-colitis/
If you are required to provide additional personally identifiable information to access a particular component of the Services, or if we would like to use personally identifiable information that you have previously provided in a manner not otherwise permitted under this Privacy Policy, we will explain how we intend to use such personally identifiable information at the time of collection and will require your consent at that time to any such collection and use. Continuing Medical Education When you participate in a Continuing Medical Education (CME) or a Continuing Education (CE) activity through the Services, you may be asked to provide personally identifiable information such as your name and mailing address. In addition to personally identifiable information, aggregated non-personally identifiable information about the activities undertaken by CME/CE participants is recorded. Information that you provide in connection with your participation in CME/CE activities, either when registering or requesting credit, may be used in several ways: Medscape is accredited by the Accreditation Council for Continuing Medical Education (ACCME) the American Nurses Credentialing Center, and the Accreditation Council for Pharmacy Education to provide continuing education to physicians, nurses and pharmacists, respectively. As an accredited entity, Medscape is required to periodically submit aggregated data about CME/CE participants and the CME/ CE activities that Medscape certifies. Medscape also provides personally identifiable information to other accredited CME/CE providers who certify CME/CE activities offered through the Services, as necessary for their fulfillment of their reporting obligations to the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years; and Supporters of CME/CE activities will receive only aggregated data about CME/CE activities that they support. The Medscape editorial staff has access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Medscape may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and evaluating its education activities. Information from Outside Sources We may collect additional information about registered users from third party sources to assist us in providing the Services. For example, we use such information to verify and update registration information and confirm licensure status. Other Information Discussion Boards: When you post a message to a discussion board, your basic profile will be available for all registered users to see. This basic profile consists of your name, specialty and geographic information. You may, at your option, choose to display additional information in your profile. You should not post any information about you or any other person (including any patient) to a discussion board or other public forum if you want to keep such information private or you are required by law to keep such information private. have a peek at this web-site http://emedicine.medscape.com/article/183084-treatment
Vedolizumab, an intravenous antibody medication, offers new hope for the approximately four million people who suffer from the auto-immune diseases, say researchers who led two clinical trials, the results of which were published in the New England Journal of Medicine on Wednesday. The treatment resulted in remission and allowed patients to stop taking prednisone, a drug with ample side effects used to treat both diseases. "The two trials showed highly encouraging results for patients suffering from moderate to severe Crohn's disease and ulcerative colitis when conventional therapy such as steroids, immune suppressive drugs" and other drugs failed, said William Sandborn of the UC San Diego School of Medicine, who led the Crohn's study. "These latest findings will potentially lead to a new drug therapy that will improve a patient's overall lifestyle," Sandborn said. Vedolizumab, created by Japan's Takeda laboratory, blocks immune system cells that release proteins called cytokines that trigger inflammation, causing diarrhea and tissue damage in the small intestine and colon. The medication could help patients avoid the weight gain, nausea and headaches associated with other treatments for the diseases. Patients could also forgo the steroids and immunosuppressive medication that put them at risk for infection. Crohn's disease and ulcerative colitis cause abdominal pain, diarrhea, intestinal bleeding and weight loss. In severe cases, bowel obstruction, colon cancer, malnutrition and abscesses that necessitate removal of part of the bowel and colon can occur. Clinical trials in 34 countries followed 895 patients with ulcerative colitis and 1,115 patients with Crohn's disease, between the age of 18 and 80. Patients were treated for a year and saw effects after six weeks. address http://www.foxnews.com/health/2013/08/22/new-treatment-could-help-those-with-crohns-colitis/
Replies